Literature DB >> 7675944

Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex.

G Tanda1, R Frau, G Di Chiara.   

Abstract

Fluoxetine and desipramine, two antidepressants that block selectively the serotonin and the noradrenaline carrier, increase extracellular dopamine concentrations in the prefrontal cortex of freely-moving rats. This effect is calcium dependent and is prevented, in the case of fluoxetine but not desipramine, by systemic pretreatment with low doses or by low concentrations in the dialyzing Ringer of the potent 5-HT3 antagonist ICS 205930. Fluoxetine, but not desipramine, increases extracellular serotonin concentrations in the prefrontal cortex. The results indicate that selective serotonin reuptake blockers increase extracellular dopamine in the prefrontal cortex by stimulating local 5-HT3 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675944     DOI: 10.1007/bf02246048

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats.

Authors:  J Chen; W Paredes; H M Van Praag; J H Lowinson; E L Gardner
Journal:  Synapse       Date:  1992-03       Impact factor: 2.562

2.  Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.

Authors:  E Carboni; G L Tanda; R Frau; G Di Chiara
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

3.  Mesencephalic dopamine neurons projecting to neocortex.

Authors:  O Lindvall; A Björklund; R Y Moore; U Stenevi
Journal:  Brain Res       Date:  1974-12-06       Impact factor: 3.252

4.  Histochemical confirmation for dopaminergic innervation of the rat cerebral cortex after destruction of the noradrenergic ascending pathways.

Authors:  B Berger; J P Tassin; G Blanc; M A Moyne; A M Thierry
Journal:  Brain Res       Date:  1974-12-06       Impact factor: 3.252

Review 5.  Use of specific serotonin uptake inhibitors as antidepressants.

Authors:  L Lemberger; R W Fuller; R L Zerbe
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

6.  A functional anatomical study of unipolar depression.

Authors:  W C Drevets; T O Videen; J L Price; S H Preskorn; S T Carmichael; M E Raichle
Journal:  J Neurosci       Date:  1992-09       Impact factor: 6.167

7.  Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites.

Authors:  A Imperato; G Di Chiara
Journal:  J Neurosci       Date:  1984-04       Impact factor: 6.167

8.  Serotonin release estimated by transcortical dialysis in freely-moving rats.

Authors:  E Carboni; G Di Chiara
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

9.  Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness.

Authors:  M S Buchsbaum; J Wu; L E DeLisi; H Holcomb; R Kessler; J Johnson; A C King; E Hazlett; K Langston; R M Post
Journal:  J Affect Disord       Date:  1986 Mar-Apr       Impact factor: 4.839

10.  Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?

Authors:  G Tanda; E Carboni; R Frau; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

View more
  11 in total

1.  Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain.

Authors:  T Kobayashi; K Matsuno; M Murai; S Mita
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

Review 4.  Dopamine: Functions, Signaling, and Association with Neurological Diseases.

Authors:  Marianne O Klein; Daniella S Battagello; Ariel R Cardoso; David N Hauser; Jackson C Bittencourt; Ricardo G Correa
Journal:  Cell Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.046

5.  Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex.

Authors:  G Tanda; R Frau; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

6.  Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat.

Authors:  G Tanda; V Bassareo; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

7.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

8.  Electrolytic lesions and pharmacological inhibition of the dorsal raphe nucleus prevent stressor potentiation of morphine conditioned place preference in rats.

Authors:  Matthew J Will; Andre Der-Avakian; Sondra T Bland; Ruth E Grahn; Sayamwong E Hammack; Peter D Sparks; Julie L Pepin; Linda R Watkins; Steven F Maier
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

Review 9.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

10.  MDMA (Ecstasy) decreases the number of neurons and stem cells in embryonic cortical cultures.

Authors:  Anna M S Kindlundh-Högberg; Chris Pickering; Grzegorz Wicher; David Hobér; Helgi B Schiöth; Asa Fex Svenningsen
Journal:  Cell Mol Neurobiol       Date:  2009-06-19       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.